ZBIO
Zenas BioPharma, Inc. (ZBIO) Economic Moat Analysis (2026)
Overall Score
Pricing Power
Gross margin remains deeply negative at -59.7%, indicating the company lacks pricing power and is still selling below cost.
Revenue per share is only 0.016 while price-to-sales is 1972.9x, suggesting valuation is disconnected from current monetization rather than evidence of moat strength.
Scale Efficiency
Operating leverage is absent, with operating margin at -475.6% and EBITDA margin at -457.3%.
Asset turnover is just 0.0014x, showing extremely poor revenue generation from the asset base.
Customer Stickiness
Receivables turnover of 1.25x and days sales outstanding of 292 imply slow collections and limited evidence of strong customer lock-in.
No news or metrics indicate recurring revenue durability or switching-cost advantages.
Cost Advantage
R&D to revenue at 380.1% and SG&A to revenue at 61.4% point to a very high cost structure rather than a durable cost advantage.
Free cash flow and operating cash flow remain negative, reinforcing the absence of operating efficiency.
Network Effects
There is no evidence of network effects in the current metrics, and the company is not yet generating scale-driven engagement or monetization benefits.
The business remains too small and unprofitable to infer self-reinforcing ecosystem dynamics.
Intangible Assets
Intangibles are 0% of total assets, so the balance sheet does not show meaningful intangible asset support for a moat.
High R&D intensity may indicate product development effort, but it has not translated into durable profitability or returns.
Switching Costs
No evidence of contractual lock-in, subscription retention, or other switching-cost indicators appears in the data.
Negative margins and weak cash generation suggest customers are not yet paying for embedded workflow dependence.
Regulatory Structural Barriers
The current data does not show meaningful regulatory barriers or protected market access.
A strong current ratio of 9.9x supports liquidity, but liquidity is not a moat and does not create structural barriers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Zenas BioPharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

